Meeting
2024 ASCO Genitourinary Cancers Symposium
Impact of standard-of-truth method on evaluation of a diagnostic PET radiopharmaceutical: Learnings from the phase 3 SPOTLIGHT study.
Authors
Benjamin H. Lowentritt
Chesapeake Urology Research Associates, Towson, MD
Benjamin H. Lowentritt , Albert Chau , Phillip Davis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Diagnostics and Imaging
Clinical Trial Registration Number
NCT04186845
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 39)
DOI
10.1200/JCO.2024.42.4_suppl.39
Abstract #
39
Poster Bd #
A18
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) withbiochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.
First Author: Frederic Pouliot
Poster
2024 ASCO Genitourinary Cancers Symposium
Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: A surrogate of pelvic lymph node dissection? Follow-up analysis of a multicenter prospective phase 3 imaging trial.
First Author: Loic Djaileb
Poster
2023 ASCO Annual Meeting
Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: A surrogate of pelvic lymph node dissection? Follow-up analysis of a multicenter prospective phase 3 imaging trial.
First Author: Loic Djaileb
Poster
2023 ASCO Annual Meeting
89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma: Results from phase 3 ZIRCON study.
First Author: Brian M. Shuch